期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 107, 期 4, 页码 735-737出版社
WILEY
DOI: 10.1002/cpt.1793
关键词
-
资金
- FDA [HHSF223201710186C]
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute [R01HL141505]
Actionable real-world evidence (RWE) requires accurate estimation of causal treatment effects. Calibration of RWE against randomized controlled trials (RCTs) is sometimes done to demonstrate that RWE can support the same causal conclusion as RCTs. Disagreements can occur when studies in each pair asked different questions in different populations or due to the presence of residual bias. Distinguishing among reasons for differences will impact the level of confidence in RWE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据